✨ Free AI Report
Marker Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Marker Therapeutics, Inc.
Research Preview

Marker Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Marker Therapeutics is a clinical-stage immuno-oncology company developing novel cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company's lead program focuse...

Analyst-debate audio for Marker Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Marker Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Marker Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
4/ 10Mixed

Cyborg Score thesis

Early-stage cell therapy company with differentiated MAR-T platform showing clinical promise but facing significant commercial...

Read the full analyst-debate transcript →
Industry Cell-based immunotherapy for oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 22, 2026
AI-Verified Research
30+ Page Report

Get the Latest Marker Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Marker Therapeutics, Inc. Overview

Pro stress-test →

Marker Therapeutics is a clinical-stage immuno-oncology company developing novel cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company's lead program focuses on Multi-Antigen Recognizing (MAR) T cell technology with promising early clinical data demonstrating both safety and efficacy.

Strategic Profile

Pro stress-test →

The company's MAR-T cell technology achieved an 84.6% disease control rate in pancreatic cancer when combined with frontline chemotherapy. Marker plans a company-sponsored trial with expanded antigen targets, higher cell doses and lymphodepletion, with anticipated clinical initiation in H1 2026, supported by non-dilutive government funding.

Competitive Landscape

Pro stress-test →

Marker competes in the CAR-T and multi-antigen T cell therapy space against established players including Juno Therapeutics (Celgene/Bristol Myers Squibb), Kite Pharma (Gilead), and emerging competitors. The MAR-T platform differentiates through multi-antigen targeting and apparent tolerability, though the company lacks commercial-stage competitors directly.

Industry Context

Marker Therapeutics, Inc. operates in Cell-based immunotherapy for oncology.

Key facts

Founded: 1991 · Headquarters: Houston, TX · Employees: Unknown · Revenue: Minimal/Pre-commercial · Market cap: $~300M (micro-cap)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Marker Therapeutics, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Marker Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T Cell TherapyEngineered cell immunotherapies for hematologic malignancies→YescartaCAR-T cell therapy for lymphomas→TecartusCAR-T cell therapy for B-cell malignancies→

Compare Marker Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Marker Therapeutics, Inc. operates in Cell-based immunotherapy for oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Cell-based immunotherapy for oncology research →
NEW · MCP server

Ask your AI assistant about Marker Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Marker Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Marker Therapeutics, Inc. do this quarter?”
“Is Marker Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Marker Therapeutics, Inc. do?+
Marker Therapeutics is a clinical-stage immuno-oncology company developing novel cell-based immunotherapies and peptide-based vaccines for hematological malignancies and solid tumors. The company's lead program focuse...
What is Marker Therapeutics, Inc.'s Cyborg Score?+
Marker Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Marker Therapeutics, Inc.'s main competitors?+
Named competitors include CAR-T Cell Therapy, Yescarta, Tecartus. The full competitive landscape is in the AskCyborg report.
How can I get the full Marker Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Marker Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Marker Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9Anthropic9Dubai Electricity and Water Authority (DEWA)9Emaar Development PJSC9Gold Fields Limited9Western Digital Corporation9Advantest Corporation9Fast Retailing Co., Ltd.9JPMorgan Chase & Co.9Siemens AG9Space Exploration Technologies Corp8Arcellx, Inc.8Gentili Mosconi S.p.A.8Neurogene Inc.8Selvaag Bolig ASA8Satellogic Inc.8Klaveness Combination Carriers ASA8Unusual Machines, Inc.8Shoei Co., Ltd.